Tenaya Therapeutics, Inc. Common Stock
$0.68
$0.01 (+1.06%)
$0.67Day Range$0.71
Key Statistics
Market Cap
$150.73M
Shares Outstanding
224.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 30, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$0.68
Day High
$0.71
Day Low
$0.67
Volume
4.87M
VWAP
$0.68
Prev Close
$0.67
Transactions
--
Acc. Volume
--
About Tenaya Therapeutics, Inc. Common Stock
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283670 employees171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080415-865-2066IPO Jul 30, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001858848
- Composite FIGI
- BBG00FPMK2S3
- Share Class FIGI
- BBG00FPMK2T2
- Ticker Root
- TNYA
- SIC Code
- 2836
About Tenaya Therapeutics, Inc. Common Stock (TNYA) Stock
Tenaya Therapeutics, Inc. Common Stock (TNYA) closed the 2026-09-18 session at $0.68, up 1.06% versus the previous close (+0.01). The stock opened at $0.68 and traded between $0.67 and $0.71 during that session. Session trading volume was 4.9M shares. The volume-weighted average price (VWAP) is $0.68.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Tenaya Therapeutics, Inc. Common Stock has a market capitalization of $150.7 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. TNYA is listed on the XNAS exchange. The company employs approximately 70 people. Tenaya Therapeutics, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2021-07-30.
On this page you can find market TNYA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.